|
Note: Print this page for easy reference
|
Protecting Bone Health
in Oncology Tuesday, January 16, 2007, 3 PM Eastern Wednesday, January 24, 2007, 12 Noon
Eastern Tuesday, January 30, 2007, 12 Noon
Eastern Please note: These broadcasts are
available in all time zones.
|
|
Sponsored by Supported by an educational grant from Novartis. Release Date: January 2007 Credit Termination: January 2008 TARGET AUDIENCE This activity is designed for oncologists, oncology nurses, urologists, pharmacists and other clinicians involved in the care of patients with cancer. STATEMENT OF NEED Protecting bone health for cancer patients has become an increasing priority for oncologists. Metastasis to bone occurs in approximately 75% of women with advanced metastatic breast cancer. Bone metastases are also found in an estimated 40% of patients with advanced lung cancer, and are associated with poor outcomes, and survival times of less than 6 months. In addition, bone complications are very common in patients with multiple myeloma, and those with prostate cancer and other solid tumors. With advances in cancer treatment, patients can now look forward to increased survival times, but they also are at increased risk for bone loss associated with cancer therapy. For example, chemotherapy can cause a decrease in gonadal steroid levels of estrogen and androgen, resulting in bone loss. Furthermore, cytotoxic therapies cause further bone loss by inhibiting osteoblasts; in particular, patients on androgen deprivation therapy (ADT) experience accelerated bone loss. Patient health-related quality of life deteriorates markedly when bone metastasis occurs—the most common cause of pain associated with advanced stages of cancer. Severe bone pain may even require narcotic or radiation therapy for control. Bone metastasis is associated with skeletal–related events (SREs) of fracture and spinal cord compression that can cause patients to lose independence, further diminishing their quality of life. Pathological fractures have been correlated with mortality in patients with a variety of solid tumors and metastasis to bone. Further, hypercalcemia of malignancy results from calcium release by degraded bone, and causes life-threatening complications. The burden of SREs for patients with cancer relates not only to increased morbidity and mortality, but also to increased overall health care costs (on average by an additional $10,000 per patient.) The goals of bone metastasis therapy are to control pain, reduce morbidity, and improve patient quality of life. Currently radiation, surgery, bisphosphonates and analgesics are used as treatments for bone metastasis and SREs. Therapy with bisphosphonates such as pamidronate and zoledronic acid protect bone health by decreasing SREs and treating hypercalcemia of malignancy. As of 2003, the American Society of Clinical Oncology (ASCO) recommends intravenous bisphosphonate pamidronic acid or zoledronic acid every 3-4 weeks for women with breast cancer and evidence of bone destruction is therapy. These revised guidelines underscore the importance of bone health issues in cancer care. Physicians who treat patients with cancer will benefit from educational programs that present emerging data for prevention and treatment of bone disease, with an emphasis on early identification and treatment, in addition to the safety profile of available therapies. Improving patient quality of life by protecting bone health in cancer-related healthcare has become increasingly important, especially since current therapies continue to reduce morbidity and mortality of cancer. ACTIVITY GOAL The goals of this activity are to educate
oncologists, oncology nurses, urologists , other health care professionals
involved in the treatment and supportive care of patients with
breast cancer, lung cancer, prostate cancer, and multiple myeloma
and to provide an understanding of recent clinical data
surrounding the use of bisphosphonate therapy in various tumor types that
will ultimately play an important role in protecting bone health in patients
with metastasis. LEARNING
OBJECTIVES
Upon
completion of this activity, participants should be better able to:
CREDIT DESIGNATION
Albert
Einstein College of Medicine designates this educational activity for a
maximum of 1.5 AMA PRA Category
1 Credit(s)™. Physicians should only claim
credit commensurate with the extent of their participation in the activity. This activity has been planned and
produced in accordance with the ACCME Essentials. ACCREDITATION STATEMENT
Albert Einstein College of Medicine is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical
education for physicians. PHARMACY ACCREDITATION STATEMENT
Grievance Policy: A participant, sponsor, faculty member
or other individual wanting to file a grievance with respect to any aspect of
a program sponsored or co-sponsored by the UTCOP may contact the Associate
Dean for Continuing Education in writing. The grievance will be reviewed and
a response will be returned within 45 days of receiving the written
statement. If not satisfied, an appeal
to the Dean of the NURSES INFO Nurses: Nurses attending this program will receive 1.5 contact hour. This continuing nursing education
activity has been submitted to METHOD OF PARTICIPATION There are no fees for participating in, and receiving CME credit
for, this activity. During the period January 2007 through January 2008,
participants must: 1) read the learning objectives and faculty disclosures;
2) study the educational activity; 3) complete the posttest by recording the
best answer to each question in the answer key on the evaluation form; 4)
complete the evaluation form; and 5) mail or fax the evaluation form with
answer key to Albert Einstein College of Medicine. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and a completed posttest with a score of
70% or better. Your statement of credit will be mailed to you within 3 weeks. FACULTY/EDITORIAL BOARD James R.
Berenson, MD Medical
& Scientific Director Institute for Myeloma & Bone Cancer Research Los
Angeles, CA James McKiernan, MD Assistant
Professor of Urology Vice Chairman, Department of Urology Corey Langer Associate
Professor of Medicine Medical Director, Thoracic Oncology Allan
Lipton, MD Professor
of Medicine Chief,
Division of Oncology Site
Director, Assistant Professor, Department of Radiation
Oncology CONFLICT OF INTEREST STATEMENT The Albert Einstein College of Medicine also requires that
faculty participating in any CME activity disclose to the audience when
discussing any unlabeled or investigational use of any commercial product, or
device, not yet approved for use in the FACULTY DISCLOSURES The Faculty of Protecting
Bone Health in Oncology Satellite Broadcast have
indicated the following disclosure information: James
Berenson, MD Grant/Research Support:
Novartis, Celgene, Cephalon, Millennium, OrthoBiotech, AMGEN, Cytogen, Consultant/Advisory
Board: Novartis, Celgene, Cephalon,
Millennium, OrthoBiotech, AMGEN, Cytogen, Speakers
Bureau/Honorarium: Novartis, Celgene,
Cephalon, Millennium, OrthoBiotech, AMGEN, Cytogen, James
McKiernan, MD Grant/Research Support: None Consultant/Advisory
Board: None Speakers
Bureau/Honorarium: Novartis Corey J.
Langer Grant/Research
Support: Bristol-Myers Squibb,
Pharmacia, Lilly, Schering-Plough research Institute, Aventis, Amgen, Cell
Therapeutics Inc., OrthoBiotech (OBI), Celgene, Vertex, Genentech,
Astrazeneca, Pfizer, Active Biotech, Medimmune, Millenium, Novartis Consultant/Advisory
Board: Bristol-Myers Squibb, ImClone, Sanofi-Aventis, Pharmacia,
Intrabiotics, GlaxoSmithKline, Pharmacyclics, Amgen, AstraZeneca, Novartis,
Genentech, Bayer, Millenium Speakers
Bureau/Honorarium: Bristol-Myers Squibb, Aventis, Lily, OrthoBiotech,
Genentech Allan
Lipton, MD Grant/Research Support:
Procter & Gamble, Abbott Consultant/Advisory
Board: Novartis, AMGEN, Procter & Gamble, Endo, Abbott Speakers
Bureau/Honorarium: Novartis Grant/Research Support:
None Consultant/Advisory
Board: None Speakers
Bureau/Honorarium: Genentech, Amgen, Novartis The staff of CCME of Albert Einstein College of Medicine have no disclosures to report other than the following: Steven Jay Feld, or a member of his household own securities in: Alkermes,
Inc., Bioheart, Inc., Marshall Edwards, Inc. and Sanofi-Aventis DISCLOSURE OF UNLABELED USE This educational activity may contain
discussion of published and/or investigational uses of agents that are not
indicated by the FDA. The opinions expressed in this
educational activity are those of the faculty and do not necessarily
represent the views of James Berenson, MD – Velcade (Myeloma use
in Combination with Chemotherapy) Arsenic trioxiede (Myeloma Use) Thalomid, Revlimid (Myeloma Use) Zometa (MGUS use) Celebrex (Myeloma use) Quadramet (Myeloma use) DISCLAIMER Participants have an implied
responsibility to use the newly acquired information to enhance patient
outcomes and their own professional development. The information presented in
this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patients’ conditions and possible
contraindications or dangers in use, review of any applicable manufacturer’s
product information, and comparison with recommendations of other authorities. CME CREDIT To obtain a certificate of
completion, participants must complete the posttest and evaluation form, and
mail or fax to Only those who answer at least 70% of
the test questions correctly will be eligible to receive credit. If you have
any questions regarding total number of credits received to date, please call
718-920-6674. |
|
|
©Copyright VitalSigns Healthcare
TV |
|
